Statements (48)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:associated_with |
Liver cancer
Liver cirrhosis Chronic liver disease |
| gptkbp:cause |
gptkb:virus
|
| gptkbp:community_health |
Requires ongoing surveillance
Significant in endemic regions |
| gptkbp:diagnosis |
Blood test
HCV RNA test HCV antibody test |
| gptkbp:diseases |
Can lead to chronic hepatitis
Can lead to extrahepatic manifestations Can lead to liver failure |
| gptkbp:duration |
8 to 12 weeks
|
| gptkbp:epidemiology |
Less common than HCV-1 globally
More prevalent in certain populations |
| gptkbp:genetic_diversity |
Higher genetic diversity than HCV-1
|
| gptkbp:genotype |
2
|
| https://www.w3.org/2000/01/rdf-schema#label |
HCV-2
|
| gptkbp:is_a |
gptkb:virus
|
| gptkbp:is_recognized_as |
1990s
|
| gptkbp:is_vulnerable_to |
No vaccine available
|
| gptkbp:prevalence |
Lower than HCV-1
|
| gptkbp:region |
gptkb:Southeast_Asia
West Africa |
| gptkbp:research_focus |
Vaccine development
Genetic studies Epidemiological studies Improved treatment regimens Understanding viral pathogenesis |
| gptkbp:risk_factor |
Blood transfusions
Intravenous drug use Sexual transmission Tattooing with unsterile equipment Unsterile medical equipment |
| gptkbp:symptoms |
Fatigue
Abdominal pain Jaundice |
| gptkbp:transmission |
gptkb:blood
|
| gptkbp:treatment |
Antiviral therapy
Direct-acting antivirals Higher than 90% with modern therapies Interferon-based therapy |
| gptkbp:type_of |
2a
2b 2c |
| gptkbp:bfsParent |
gptkb:Hepacivirus
|
| gptkbp:bfsLayer |
5
|